StockData
argenx SE logo

argenx SE (ARGX) income statement

ARGXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 19, 2026Score 5/30
$925.70−16.34 (-1.73%)

Close on Nov 20, 2026Market cap –P/E 47.3Yield –

See a number that looks wrong?